DETERMINE (Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly defined Indications using a National Evaluation platform trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations. (DETERMINE)

Research summary

The overall aim of the trial is to evaluate the efficacy of licensed targeted therapies in unlicensed indications,in rare adult,paediatric and TYA cancers with actionable genomic alterations (including common cancers with rare actionable alterations) and to identify genomic,transcriptomic and immune contextual influences on response to therapy. The ultimate aim is to transition positive findings to the NHS (Cancer Drugs Fund [CDF]) to provide new treatment options for patients with rare malignancies.

Principal Investigator

Dr Sarah Pratap

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1004057